Astellas Pharma Buys Iveric Bio: Help Offset Upcoming Patent Expiry of XTANDI
Acquisition of Iveric Bio's key drug asset ACP should offer protection against upcoming patent expiry of XTANDI. The whole deal is based on a late...
Astellas Pharma (4503 JP): New Acquisition to Add Promising Drug Candidate in New Therapeutic Area
Astellas Pharma is acquiring Iveric Bio for ~$5.9B. Iveric’s lead drug candidate ACP will be a revenue-generating pillar to compensate for the...
Ophthotech: What Is Next?
We listened to the conference call by Ophthotech Corp (OPHT US) management (link). The results of the phase 3 trial were shocking to many investors...
New Long Position: Novel Drug for Wet-AMD, a Common Cause of Blindness, and Upcoming Catalyst.
We opened a new long position today in Ophthotech Corp (OPHT US), an emerging biotechnology company that is developing novel drugs for wet-type...
No more insights